Next Article in Journal
Variability in Characterizing Escherichia coli from Cattle Feces: A Cautionary Tale
Next Article in Special Issue
Diversity of Myxobacteria—We Only See the Tip of the Iceberg
Previous Article in Journal / Special Issue
Evaluation of Antimicrobial, Enzyme Inhibitory, Antioxidant and Cytotoxic Activities of Partially Purified Volatile Metabolites of Marine Streptomyces sp.S2A
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessReview

Antiviral Compounds from Myxobacteria

Department of Microbial Drugs, Helmholtz Centre for Infection Research and German Centre for Infectio Research (DZIF), Partner Site Hannover/Braunschweig, Inhoffenstrasse 7, 38124 Braunschweig, Germany
Department of Microbial Strain Collection (MISG), Helmholtz Centre for Infection Research (HZI), Inhoffenstrasse 7, 38124 Braunschweig, Germany
Author to whom correspondence should be addressed.
Microorganisms 2018, 6(3), 73;
Received: 25 May 2018 / Revised: 13 July 2018 / Accepted: 17 July 2018 / Published: 19 July 2018
PDF [1652 KB, uploaded 19 July 2018]


Viral infections including human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), and hepatitis C virus (HCV) pose an ongoing threat to human health due to the lack of effective therapeutic agents. The re-emergence of old viral diseases such as the recent Ebola outbreaks in West Africa represents a global public health issue. Drug resistance and toxicity to target cells are the major challenges for the current antiviral agents. Therefore, there is a need for identifying agents with novel modes of action and improved efficacy. Viral-based illnesses are further aggravated by co-infections, such as an HIV patient co-infected with HBV or HCV. The drugs used to treat or manage HIV tend to increase the pathogenesis of HBV and HCV. Hence, novel antiviral drug candidates should ideally have broad-spectrum activity and no negative drug-drug interactions. Myxobacteria are in the focus of this review since they produce numerous structurally and functionally unique bioactive compounds, which have only recently been screened for antiviral effects. This research has already led to some interesting findings, including the discovery of several candidate compounds with broad-spectrum antiviral activity. The present review looks at myxobacteria-derived antiviral secondary metabolites. View Full-Text
Keywords: myxobacteria; antivirals; secondary metabolites; HIV; Ebola; hepatitis viruses myxobacteria; antivirals; secondary metabolites; HIV; Ebola; hepatitis viruses

Graphical abstract

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Mulwa, L.S.; Stadler, M. Antiviral Compounds from Myxobacteria. Microorganisms 2018, 6, 73.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Microorganisms EISSN 2076-2607 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top